信达证券给予万孚生物买入评级，业绩短期承压，静待扰动消退后发展向好

Group 1 - Core viewpoint: Cinda Securities issued a report on August 21, giving Wanfu Biology (300482.SZ, latest price: 23.01 yuan) a buy rating [2] - Reason for rating: The toxicology testing business is recovering growth, while testing for infectious and chronic diseases is under pressure [2] - Short-term profitability is under pressure, but innovation is expected to drive long-term growth [2]